---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Epidemiology and eligible population inputs"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Epidemiology and eligible population inputs. Topics: Company estimate of the U.S. treated and diagnosed GA population; Company estimate of GA prevalence in the United States and worldwide; Pegcetacoplan PBAC financial estimates: prevalence, eligibility, and uptake inputs; Avacincaptad pegol PBAC financial estimates: incidence, prevalence, and non-subfoveal proportion. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics/epidemiology-and-eligible-population-inputs"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Epidemiology and eligible population inputs

<a id="heading-4.2.3"></a>

## 4.2.3 Epidemiology and Eligible Population Inputs

<a id="topic-4.2.3-1"></a>

### Budget impact model of vonaprument: eligible population

No evidence found.

<a id="topic-4.2.3-2"></a>

### Company estimate of the U.S. treated and diagnosed GA population

> “Based on market reports, approximately 75,000 patients are being actively treated with available therapies in the US, representing ~10% of the 800,000 people diagnosed with GA/under the care of retina specialists, but only about 5% of the 1.5M US population with GA”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

<a id="topic-4.2.3-3"></a>

### Company estimate of GA prevalence in the United States and worldwide

> “GA affects more than an estimated one million people in the United States and eight million people worldwide”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-4.2.3-4"></a>

### Pegcetacoplan PBAC financial estimates: prevalence, eligibility, and uptake inputs

> “Prevalence of 1.29% (patients aged 60 years and older) based on late AMD and the proportion of patients with GA as reported in Australian National Eye Health Survey (NEHS).”
> “Proportion of patients with bilateral GA – 63.5% (IRIS) and proportion of patients with non-subfoveal GA in one eye and subfoveal GA in the fellow eye 33.9% (FRB!)”
> “The uptake rate was based on the uptake of ranibizumab in its first five full years of listing (2008-2012), adjusted to account for differences in annual injection rates.”
> “DUSC considered that there may be “warehoused” patients specifically waiting for this drug to become available on the PBS.”

Source: [Pharmaceutical Benefits Advisory Committee pegcetacoplan (2025)](https://www.pbs.gov.au/industry/pbac/psd/2025/11/pegcetacoplan-psd-november-2025.pdf?variant=3)

<a id="topic-4.2.3-5"></a>

### Avacincaptad pegol PBAC financial estimates: incidence, prevalence, and non-subfoveal proportion

> “0.17%, calculated from the cumulative 10-year incidence rate of 1.7% for GA reported in Wang et. al”
> “0.52%, weighted prevalence rate based on the prevalence rates reported for non-indigenous (aged ≥ 50 years old) and indigenous Australians (aged ≥ 40 years old) in Keel et. al”
> “31.60%, based on a retrospective analysis of patients in the IRIS registry with less than 24 months of follow-up data”
> “Prevalent patients were included in year 1 only.”
> “The prevalence rate for non-indigenous Australians when patients aged < 50 years old are excluded was 0.26% (compared to 0.17%).”

Source: [Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026)](https://www.pbs.gov.au/industry/pbac/psd/2026/03/avacincaptad-pegol-psd-march-2026-a1151.pdf?variant=3)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
